Clinical Trial: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)
Brief Summary: The purpose of this study is to determine whether PTK787/ZK 222584 is effective in treating hemangioblastoma of the brain and/or retina in patients with von Hippel-Lindau disease. The study will also assess safety and tolerability of PTK787/ZK 222584, and changes in markers of angiogenesis (new blood vessel growth).
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: Evaluate efficacy
Original Primary Outcome:
Current Secondary Outcome:
- Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
- To explore the correlation of the pharmacokinetics
- To assess changes in surrogate markers of angiogenesis
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: January 21, 2003
Date Started: February 2003
Date Completion:
Last Updated: March 2, 2017
Last Verified: February 2011